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ABSTRACT. Due to the critical role of the large neutral amino acid transporter-1 (LAT-1) in 
promoting tumor growth and proliferation, it is fast emerging as a highly attractive biomarker 
for the imaging and treatment of human malignancies, including breast cancer. Whilst multi-
branched gold nanoparticles (AuNPs) have emerged as a promising modality in the 
photothermal therapy (PTT) of cancers, some of the key challenges limiting their clinical 
translation lies in the need to develop reproducible and cost-effective synthetic methods as 
well as the selective accumulation of sufficient AuNPs at tumor sites. In this study, we report 
a direct seed-mediated synthesis of monodispersed multi-branched AuNPs using the catechol-
containing LAT-1 ligands, L- and D-dopa, to confer active cancer targeting without the need 
for additional conjugation with targeting moieties such as peptides or antibodies. Nanoflower-
like AuNPs (AuNF) with diameters of approximately 46, 70 and 90 nm were obtained and 
were found to possess excellent colloidal stability and biocompatibility. A significantly higher 
cellular accumulation of the L- and D-dopa functionalized AuNFs was observed in a panel of 
breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-468, and MDA-MB-453) when 
compared to the non-targeting control AuNFs synthesized with dopamine and 4-ethylcatechol. 
Importantly, no significant difference in uptake between the targeting and non-targeting 
AuNFs was observed in a non-tumorigenic MCF-10A breast epithelial cell line, hence 
demonstrating tumor selectivity. For PTT of breast cancer, Ag+ was introduced during 
synthesis to obtain L-dopa functionalized nanourchin-like AuNPs (AuNUs) with strong near 
infrared (NIR) absorbance. The L-dopa functionalized AuNUs mediated effective 
photothermal ablation of the triple negative MDA-MB-231 breast cancer cell line as well as 
sensitized the cells to the anticancer drugs cisplatin and docetaxel. This work may provide 
new insights on the facile preparation of cancer targeting multi-branched AuNPs with 
potential for the in vivo PTT of breast cancer.    
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1. Introduction 
Breast cancer is the most common cancer among women and is one of the leading causes 
of morbidity and mortality worldwide.1 Triple negative breast cancers (TNBCs), in particular, 
pose a major clinical challenge as they are refractory to the various targeted hormonal 
therapies available and have a high risk of recurrence.2 In recent years, photothermal therapy 
(PTT) in which light energy is converted into heat, has emerged as a promising treatment 
modality for the minimally invasive treatment of various cancers such as breast cancer, gastric 
cancer, head and neck cancer, and melanoma. Anisotropic gold nanoparticles (AuNPs) such 
as nanorods, nanoprisms, nanostars, and nanoplates have been the focus of intense research as 
PTT mediators due to their strong localized surface plasmon resonance (LSPR) effect, ease of 
synthesis and functionalization, excellent biocompatibility, and potential to be simultaneously 
used as contrast enhancement agents for non-invasive X-ray computed tomography (CT) and 
photoacoustic imaging.3-5 Additionally, the longitudinal LSPR peak of anistropic AuNPs can 
be readily tuned to the near infrared (NIR) region (650 – 900 nm) to correspond to the 
biologically transparent window in which tissues and blood minimally absorb. This property 
enables the use of NIR lasers with deeper light penetration to selectively mediate 
photothermal ablation of tumors that have taken up the nanoparticles, hence minimizing 
damage to surrounding tissues. The combination of PTT with conventional chemotherapy has 
since been proposed as an attractive therapeutic approach to improve antitumor efficacy and 
minimize side effects.4  
Despite their promise, one of the key factors limiting the successful clinical translation of 
AuNP-mediated PTT lies in the poor in vivo accumulation of nanoparticles at tumor sites.4 
AuroShell® (Nanospectra Biosciences), which are silica nanoparticles coated with thin 
PEGylated gold shells, currently represent the only AuNP-based PTT device that has been 
evaluated in clinical trials.4, 6-7 Whilst encouraging patient responses were observed in Phase I 
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and II clinical trials for recurrent/refractory head and neck cancer, primary and metastatic 
lung cancer, and prostate cancer, it was found that only 1% of the injected dose achieved 
tumor accumulation as the nanoparticles relied solely on the enhanced permeation and 
retention (EPR) effect to passively accumulate in the tumor. It could thus be envisaged that 
the incorporation of active targeting strategies to increase tumor accumulation of AuNPs 
could potentially lead to enhanced antitumor effects, less side effects, and reduced treatment 
costs during PTT. In this regard, numerous researchers have successfully investigated the 
surface conjugation of pre-synthesized AuNPs with macromolecules such as cell penetrating 
or targeting peptides, aptamers, antibodies or nanobodies for active targeting to cell surface 
receptors or molecules that are frequently overexpressed in cancer cells or its 
microenvironment.4 Such approaches, however, often involve time-consuming chemical 
conjugation, purification, and characterization procedures, as well as the use of expensive 
cross-linkers, peptides and/or monoclonal antibodies which may not be ideal in the large scale 
commercial synthesis of AuNPs for clinical use.4, 8 The continued development of facile 
synthetic methods to reproducibly obtain monodispersed cancer targeting AuNPs will 
therefore be key for their successful clinical translation as effective photothermal agents. At 
the same time, the targeting of novel receptors or transporters that are consistently 
overexpressed in different cancer types, staging, and sub-types provides advantages for the 
broad utility of these novel devices in the selective photothermal ablation of a wide range of 
malignancies.  
The large neutral amino acid transporter 1 (LAT-1) forms a functional heterodimeric 
complex with 4F2hc (or CD98) heavy chain to transport a wide range of branched or aromatic 
amino acids and their related drugs such as leucine, phenylalanine, tryptophan, L-dopa, 
triiodothyronine, and melphalan in a sodium-independent manner.9 It plays a crucial role in 
facilitating amino acid uptake for protein synthesis, metabolic activities, and regulation of 
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complex signaling pathways in rapidly dividing tumor cells and thus has been found to be 
overexpressed in the majority of human neoplasms.10 Particularly in breast cancers, LAT-1 
has been found to be frequently overexpressed in tumor cells, with little or no expression in 
normal mammary ducts or adjacent breast tissues, and its co-expression with 4F2hc is 
correlated with poor disease prognosis in the triple-negative subtype.11-12 Given its important 
role in promoting tumor proliferation, the LAT-1 represents a highly attractive, but yet poorly 
exploited, biomarker for the imaging and treatment of breast cancers.11, 13 Recently, the 
effectiveness of targeting LAT-1 for anticancer drug delivery to breast cancer and glioma was 
reported by Li et al..14-15 It was demonstrated that the use of LAT-1 targeting glutamate-
functionalized polyoxyethylene stearate PLGA nanoparticles to deliver paclitaxel led to 
significantly higher tumor accumulation and inhibition of tumor growth in a subcutaneous 
4T1 breast carcinoma mouse tumor model compared to the non-targeting control 
nanoparticles.14  
Based on these observations, we hypothesized that the incorporation of LAT-1 targeting 
moieties on AuNPs would selectively increase nanoparticle accumulation inside tumor cells 
for the PTT of breast cancer. At the same time, the judicious choice of a reducing-cum-
capping agent can simultaneously give rise to multi-branched AuNPs and present the primary 
amine, carboxylic acid, and bulky side groups that are requisite for interaction with the LAT-
1.9 This direct synthesis of multi-branched AuNPs is expected to offer significant time and 
cost savings in the preparation of active targeting AuNPs for PTT. To achieve this, we 
focused on the seed-mediated synthesis of monodispersed multi-branched AuNPs using the 
LAT-1 ligands L- and D-dopa as reducing-cum-capping agents to confer intrinsic LAT-1 
targeting properties, without the need for addition conjugation steps or the traditional use of 
cytotoxic surfactants such as cetrimonium bromide. L- and D-dopa belong to the catechol 
class of compounds which consists of two hydroxyl groups bonded to a benzene ring in the 
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ortho position. During oxidation, the two hydroxyl groups in the catechol lose four electrons 
to form quinones and are therefore capable of reducing the AuCl4- species to produce gold 
atoms.16-17 In this study, in order to improve the uniformity of the synthesized multi-branched 
AuNPs for PTT, the reduction process was conducted in the presence of pre-formed gold 
seeds which served as catalysts to promote the reduction of AuCl4- by the catechols and 
enable the selective deposition of gold atoms onto the surface of the metal clusters, thus 
avoiding secondary nucleation.18-19 Given the structural similarity of catechols to 
hydroquinone (another hydroxylated aromatic), it is likely that the former similarly promoted 
preferential deposition of gold atoms onto the active (111) facets in a kinetically driven 
manner, thereby giving rise to nanoparticles with a multi-branched nanoflower-like growth.20-
21 For a valid comparison of active targeting properties, non-targeting AuNPs with 
comparable multi-branched morphologies were synthesized using dopamine and 4-
ethylcatechol, which similarly belong to the catechol class but do not fully possess the 
functional groups recognized by the LAT-1 (i.e. both α-amino and α-carboxylic acid groups9). 
The cytotoxicities and cellular targeting capabilities of the synthesized AuNPs were first 
evaluated in a panel of breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-468, and 
MDA-MB-453) and a non-tumorigenic breast epithelial MCF-10A cell line. The functional 
versatility of this system for PTT was further demonstrated by tuning the LSPR peak of the 
synthesized AuNPs to the NIR region by exploiting the underpotential deposition effect of 
silver ions to increase the aspect ratios of the branches,22-24 yielding sea urchin-like AuNPs 
(AuNUs). The targeted PTT mediated by the AuNUs alone as well as combination with 
chemotherapeutic drugs cisplatin and docetaxel were investigated in the triple negative MDA-
MB-231 metastatic breast cancer cell line. Taken together, this study offers a new perspective 
on the facile preparation of multi-branched AuNPs with intrinsic LAT-1 targeting capabilities 
for the photothermal treatment of breast cancer.  
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2. Experimental Section 
2.1.  Materials: Gold (III) chloride trihydrate, L-3,4-dihydroxyphenylalanine (L-dopa), 
dopamine hydrochloride, 4-ethylcatechol, poly(ethylene glycol) methyl ether thiol (mPEG 
thiol) average Mn 6,000, and silver nitrate were purchased from Sigma Aldrich. D-3,4-
dihydroxyphenylalanine (D-dopa) was obtained from Santa Cruz Biotechnology. All reagents 
were used as received without further purifications. The LIVE/DEAD® Viability/Cytotoxicity 
Kit was purchased from Thermo Fisher Scientific. Milli-Q water (18.2 MΩ·cm resistivity at 
25 °C) was used for the cleaning of glassware and the synthesis of AuNPs. 
2.2. Synthesis of AuNPs:  2.2.1. Preparation of Au seeds. All glassware and stir bars were 
thoroughly cleaned with aqua regia (HCl:HNO3, 3:1 v/v) before use. Spherical gold seeds with 
a diameter of approximately 14 nm were first prepared by adding 300 µL of 388 mM sodium 
citrate to 100 mL of boiling 3.0 × 10-1 mM HAuCl4·3H2O solution under stirring. The mixture 
was kept boiling for 15 min until a wine red color was observed. The resultant citrate-capped 
AuNPs were pelleted by centrifugation (10,016 × g for 2 h) and rinsed thrice with Milli-Q 
water to remove excess reagents.  
2.2.2. Synthesis of catechol-functionalized nanoflower-like AuNPs (AuNFs). In a typical 
synthesis of 90 nm catechol-functionalized AuNFs, 100 µL of 0.1 M HAuCl4·3H2O, 144 µL 
of 3.8 × 10-1 mM spherical gold seeds, 400 µL of 1.7 mM mPEG thiol, and 4.0 mL of 15 mM 
catechol solution were sequentially added to 46.0 mL of Milli-Q water under vigorous 
stirring. The color of the mixture turned from pale yellow to pink to reddish brown, and 
finally to bluish brown within 3 min. After allowing the mixture to stir at room temperature 
for 2 h, the synthesized AuNPs were pelleted at 800 × g for 10 min, and rinsed at least thrice 
with Milli-Q water to obtain a dark blue colloidal dispersion. 46 and 70 nm catechol-
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functionalized AuNPs were synthesized in a similar manner except with the volume of 0.1 M 
HAuCl4·3H2O solution reduced to 12.5 and 50 µL, respectively. 
2.2.3. Synthesis of catechol-functionalized nanourchin-like AuNPs (AuNUs). To synthesize 
catechol-functionalized AuNUs with a LSPR excitation wavelength in the NIR region, 20 µL 
of 0.1 M HAuCl4·3H2O, 100 µL of 1.0 × 10-1 mM AgNO3, 28.8 µL of 3.8 × 10-1 mM 
spherical gold seeds, 80 µL of 1.7 mM mPEG thiol, and 300 µL of 15 mM L-dopa or 4-
ethylcatechol were sequentially added to 10 mL of water under vigorous stirring. The reaction 
was allowed to proceed at room temperature for 2 h, after which the resultant AuNUs were 
purified as described above.  
2.3. Characterization of AuNPs: Synthesized AuNPs were characterized by high 
resolution TEM (JEOL JEM-2100F) using 200 kV acceleration voltage and by UV-vis-NIR 
spectrophotometry (Agilent Cary 6000i). Samples were prepared by drying diluted AuNP 
solutions on holey carbon-coated copper grids. The core diameters, tip-to-tip lengths, and 
spike aspect ratios of the AuNUs were measured from the TEM images obtained using the 
ImageJ software. The core diameters and tip-to-tip lengths were measured twice for each 
AuNU, while four spikes per AuNU were measured from the edge of the core to the tip. The 
aspect ratio of the spikes were determined by dividing the spike length by the base width of 
the spikes. The hydrodynamic diameters and zeta-potentials of the AuNPs were measured by 
dynamic light scattering (DLS) using the Zetasizer Nano (Malvern Instrument Ltd., 
Worcestershire, UK) equipped with a He-Ne laser. Scattered light was detected at an angle of 
173˚ and at a set temperature of 25 °C. Particle size and zeta-potential measurements were 
repeated for 3 runs per sample, and reported as the mean ± standard deviation of 3 readings. 
The nanoparticle concentration of the respective samples equivalent to 1 µg/µL of gold was 
determined using NanoSight NS300 nanoparticle tracking analysis (NTA) concentration 
measurement upgrade (Malvern Instrument Ltd., Worcestershire, UK). At least 3 independent 
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samples per type of functionalized AuNP were analyzed for 3 runs per sample, and reported 
as the mean ± standard deviation of 3 readings.   
To determine the elemental gold concentration of the synthesized AuNPs, an aliquot of 
known volume was dissolved in aqua regia, diluted with Milli-Q water, and analyzed using 
inductively coupled plasma-atomic emission spectroscopy (ICP-AES; Thermo Scientific 
iCAP 6300 Duo). The surface of the functionalized AuNPs was characterized using a Thermo 
Scientific K-Alpha+ X-ray Photoelectron Spectrometer (XPS) system operating at 2 × 10-9 
mbar base pressure. This system incorporates a monochromated, microfocused Al Kα X-ray 
source (hν = 1486.6 eV) and a 180° double focusing hemispherical analyser with a 2D 
detector. The X-ray source was operated a 6 mA emission current and 12 kV anode bias. Data 
were collected at 200 eV pass energy for survey and 20 eV pass energy for core level and 
valence band spectra using an X-ray spot size of 400 µm2. A flood gun was used to minimize 
sample charging. Spectra were aligned assuming the C 1s core line to be at a binding energy 
of 285.0 eV and normalized to the Au 4f5/2 peak. All data were analyzed using the Avantage 
software package. 
2.4. Cell culture: Human breast cancer cell lines MCF-7 and MDA-MB-231 were 
maintained in MEM, while MDA-MB-453 and MDA-MB-468 were maintained in 
DMEM/F12. Both types of cell culture media were supplemented with 10% FBS, 100 U/mL 
penicillin, and 100 mg/mL streptomycin. Non-tumorigenic immortalized breast epithelial cell 
line MCF-10A was cultured using DMEM/F12 media supplemented with 5% horse serum, 20 
ng/mL EGF, 0.5 mg/mL hydrocortisone, 100 ng/mL Cholera toxin, 10 µg/mL insulin 100 
U/mL penicillin, and 100 mg/mL streptomycin. All cell lines were cultured at 37 ºC under an 
atmosphere of 5% CO2 and 95% humidified air. 
2.5. Cytotoxicity testing: The effects of AuNF treatment on cell proliferation was 
determined using the WST-1 assay. Briefly, MCF-7, MDA-MB-231, and MCF-10A were 
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seeded onto 96-well plates at a density of 1.2 × 104 cells per well, and allowed to adhere 
overnight. The cells were then treated with 0, 5, 15, 50, and 100 µg/mL of Au content for the 
various AuNFs (46, 70 and 90 nm) for 48 h. Subsequently, the cells were rinsed twice with 
PBS before 100 μL of growth media and 10 μL of WST-1 reagent were added to each well. 
The cells were incubated for 3 h at 37 °C before the absorbance reading were determined at 
440 nm using a microplate spectrophotometer. Relative cell proliferation was expressed as 
[(Asample-Ablank)/(Auntreated control-Ablank)] ×100%. Data are expressed as mean ± standard 
deviations of three replicates per concentration. 
2.6. Cellular uptake studies: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, 
and MCF-10A were respectively seeded onto 12-well plates at a density of 1.8 × 105, 2.5 × 
105, 2.5 × 105, 2.5 × 105, and 1.8 × 105 cells per well, and allowed to adhere overnight. The 
incubation media in each well was replaced with cell culture media containing 15 µg/mL Au 
content for the various AuNFs (46, 70 and 90 nm). After 12 h incubation at 37 ºC, non-
internalized AuNFs were removed, and the cells were rinsed thoroughly with 1 mL of PBS for 
5 times. The cells were then trypsinized, rinsed once with PBS, and pelleted by centrifugation 
at 1300 × rpm for 4 min. The cell pellet was digested overnight with 800 µL of aqua regia at 
room temperature. The respective samples were subsequently diluted with a known volume of 
Milli-Q water before the analysis of Au content using ICP-AES. 
The competition assay was performed by co-incubating MCF-7 cells with 0, 2, and 20 mM 
of free amino acids phenylalanine or serine and 15 µg/mL gold content of L-dopa 
functionalized AuNFs. The cells were co-incubated with free amino acids and the 
functionalized AuNFs for 5 h before being processed as described above for the analysis of 
elemental Au content using inductively coupled plasma-mass spectroscopy (ICP-MS; Perkin 
Elmer ELAN® DRC-e).  
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2.7. Preparation of cell samples for TEM imaging: MDA-MB-231 cells were seeded 
onto 6-well plates at a density of 6.25 × 105 cells/mL and allowed to adhere overnight. The 
cells were incubated with 15 µg/mL gold content of L-dopa- and 4-ethylcatechol-
functionalized AuNFs for 4 and 12 h. Following incubation, the cells were rinsed thrice with 1 
× PBS and fixed with 2% glutaraldehyde and 2% formaldehyde in 0.1M sodium cacodylate 
(pH 7.4) for 1 h at room temperature. The cells were subsequently stained with 1% osmium 
tetroxide for 30 min, rinsed thrice with Milli-Q water, and dehydrated in a series of graded 
ethanol (50%, 70%, 95%, and 100% by volume). Aided by centrifugation, the cells were then 
infiltrated with increasing concentrations of Epon/acetonitrile resin. The final resin-infiltrated 
samples were then polymerized at 100 °C for 30 min. The embedded cells were sectioned to a 
thickness of approximately 50 – 100 nm onto a water bath using an ultra-microtome (Leica 
EM UC6) equipped with a 35° diamond knife and collected onto 300 mesh copper TEM 
grids. Multiple cells (> 100 per sample) from triplicate wells per treatment were observed 
using the high-angle annular dark-field-scanning transmission electron microscope (HAADF-
STEM) mode on the FEI Titan 80–300 TEM/STEM operated at 300 kV.  
2.8. Photothermal ablation: Human MDA-MB-231 breast cancer cells were seeded at a 
concentration of 3.5 × 104 cells per well in a 96-well plate and cultured for 48 h. The cell 
culture media in each well were replaced with fresh media containing 0, 50, and 100 µg/mL 
Au content of AuNUs and returned to the incubator for three days. Following incubation, non-
internalized AuNUs in each well were removed and the cells were rinsed three times with 100 
µL of 1 × PBS before 60 µL of phenol red-free MEM containing 10% serum were added to 
each well. The cells in each well were subsequently subjected to irradiation using an 808 nm 
continuous wave laser at 9.4 W/cm2 for 3 min (spot size 0.3 cm2). After laser exposure, the 
cells were incubated for a further 24 h at 37 °C before cell viability was determined using the 
WST-1 assay. To investigate the thermal effects of extracellularly applied AuNUs following 
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laser treatment, phenol-red free cell culture media containing the respective amounts of 
AuNUs were added to the cells immediately before laser irradiation. For the LIVE/DEAD® 
viability/cytotoxicity assay, 2.1 × 104 cells per well were seeded into each well of a 4-well 
chamber slide, and subjected to a similar AuNU treatment and laser exposure protocol as 
described above, after which the cells were stained with calcein AM and ethidium 
homodimer-1 for 30 min at room temperature before being imaged under a confocal laser 
scanning microscope (Leica TCS SP8).  
The use of photothermal therapy to sensitize AuNU-treated breast cancer cells to 
chemotherapy was studied by the addition of cell culture media containing 83.3 µM cisplatin 
and 100 nM docetaxel to each well immediately after laser exposure. The cells were incubated 
with the chemotherapeutic agents for a further 24 h at 37 °C before the WST-1 assay was 
performed. 
2.9. Statistical analysis: The results obtained were analyzed using the two-tailed Student’s 
t-test to determine statistical significance (Microsoft Excel). The difference between mean 
readings was considered to be statistically significant when P < 0.05. 
 
3. Results and discussion 
3.1. Catechol-mediated synthesis and characterization of nanoflower-like AuNPs 
(AuNFs). AuNFs were synthesized by first preparing approximately 14 nm gold seeds using 
the citrate reduction method (Figure S1), followed by the selective reduction of gold ions onto 
the gold seeds using each of the four different catechols (i.e.  L-dopa, D-dopa, dopamine, and 
4-ethylcatechol) as a mild reducing-cum-surface capping agent (Figure 1a). Poly(ethylene 
glycol) methyl ether thiol (mPEG thiol), which binds to the AuNF surface via oxidative 
addition of thiol to Au was included in the synthesis to enhance colloidal stability, 
biocompatibility, and blood circulation times in vivo.25-26 The addition of mPEG thiol during 
13 
 
synthesis was indeed found to be essential for obtaining narrowly dispersed AuNPs that were 
stable during prolonged storage at 4 °C (> 1 year) as well as the ability to be re-dispersed after 
freeze-drying. As expected in a diffusion-controlled atom addition process on pre-formed 
metal seeds,27 the addition of increasing amounts of HAuCl4·3H2O gave rise to 
correspondingly larger AuNFs with diameters of approximately 46, 70 and 90 nm (by TEM; 
Figure 1b, c, and d). As seen from Table S1, the hydrodynamic diameters and zeta-potentials 
of the synthesized AuNFs ranged from 55.5 to 116.5 nm and -32.6 to -41.0 mV, respectively. 
Importantly, the synthesized AuNFs possessed narrow size distributions which could be seen 
from the TEM images (Figure 1b, c, and d) as well as from the small polydispersity indices 
(PDIs) of ≤ 0.2 obtained from DLS measurements (Table S1). This property is favorable for 
the reliable and accurate interpretation of biological effects as differently sized nanoparticles 
within a given formulation may elicit disparate cell interactions and toxicity.28 The 
synthesized AuNFs gave rise to an intense UV-vis absorption peak ranging from 563 to 649 
nm, which red-shifted with size for each functionalization type (Figure S2a).                      
High resolution TEM (HRTEM) images revealed interplanar distances of approximately 
0.233 nm and 0.206 nm, which are close to the characteristic values reported for Au (111) and 
(200) lattice planes, respectively,29 hence confirming that the multi-branched AuNFs are 
composed of Au (Figure S3). Additionally, the successful conjugation and presentation of the 
respective catechols on the surface of the AuNFs was confirmed by XPS analysis. Survey 
spectra of the 90 nm catechol-functionalized AuNFs showed a strong signal from Au 4f and 
depending on the catechol, varying signals from C, N and O 1s (Figure S4a). A small amount 
of Si, which was due to the carrier substrate used, was also observed. For all samples, the Au 
4f core level is at a binding energy of 84 eV and shows a spin orbit split of 3.6 eV, both 
typical for metallic Au (Figure S4b). The C and N 1s core levels are ideal to identify the type 
of catechol on the surface of the AuNFs. For the C 1s spectrum 3 distinct contributions can be 
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identified: C-C and C=C environments at 285.0 eV, C-OH and C-NH2 environments at 286.3 
eV, and the carboxylic group at 289.0 eV. AuNFs synthesized using L- and D-dopa were 
found to possess both carboxylic acid and amino groups, while those prepared with dopamine 
showed only the expected contributions from the amino group (Figure S4c and d). As 
expected, both signals were absent in the spectrum obtained for the AuNFs synthesized using 
4-ethylcatechol.  
To evaluate their colloidal stability, L-dopa functionalized AuNFs were incubated in 
various biologically relevant media including deionized water, 1 × PBS, cell culture media 
containing 10% v/v serum, and 100% serum and monitored for changes in hydrodynamic 
diameters by DLS over time. The AuNFs were incubated at 37 °C with continuous shaking to 
mimic blood circulation. As seen in Figure S5, the L-dopa-functionalized AuNFs remained 
stable in deionized water and 1 × PBS, with minimal changes in hydrodynamic diameters, 
which were approximately 115 and 111 nm, respectively over three days of incubation. 
Similarly, no shift in the UV-vis absorbance peaks was observed when the AuNFs were 
dispersed in 1 × PBS (Figure S2b). In serum-containing cell culture media, however, the 
AuNFs gradually increased in size from 125.9 ± 0.8 nm (t = 0 h) to 167.4 ± 0.5 nm (t = 72 h). 
A similar observation was made for the AuNFs incubated in 100% serum, with a higher initial 
diameter of 164.3 ± 2.5 nm at 0 h increasing to 186.0 ± 0.4 nm by 72 h. The increase in 
hydrodynamic diameters of the AuNFs in serum-containing media and 100% serum could 
likely be attributed to the passive adsorption of serum proteins onto the nanoparticle surface. 
Despite the size increment, the hydrodynamic diameter of the AuNFs began to plateau at 72 
h; and the resultant size of the AuNFs remained less than 200 nm – a size which still falls 
within the desired size range for passive tumor accumulation via the EPR effect and the 
promotion of cellular uptake. In addition to the relatively small sizes observed, the PDIs of the 
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AuNFs in the different media were also found to remain small (< 0.15) and relatively constant 
with time, hence suggesting that no uncontrolled aggregation of the AuNFs occurred. 
3.2.  Synthesis and characterization of sea urchin-like AuNPs (AuNUs) with NIR 
absorbance. Besides being able to control the size of the AuNFs synthesized using catechols 
in the seed-mediated approach (Figure 1b-d), the versatility of this system to tune the shape 
and therefore the LSPR peak of the multi-branched nanoparticles to the biologically 
transparent NIR region for optimal PTT was further demonstrated. This was achieved through 
the introduction of Ag+ as a shape-directing agent during the seeded growth process.22-24, 30-31 
In the presence of gold seeds, Ag+ is known to undergo reduction on gold surfaces at a 
potential less than the standard reduction potential of Ag+/Ag0 in a phenomenon known as 
‘under-potential deposition’.24, 31-32 At low concentrations of added Ag+, the reduced Ag 
atoms have been found to preferentially deposit on the more open Au (110) facets thereby 
protecting them from further growth while promoting anisotropic growth of Au atoms on the 
(111) and (100) planes.31 As seen from Figure 2a, the introduction of Ag+ enhanced the aspect 
ratio of the branches formed, giving rise to narrowly dispersed AuNUs capped with L-dopa 
and PEG on the surface. The mean diameter of the L-dopa functionalized AuNU core was 
found to be 83.9 ± 4.4 nm (Figure 2a insert), while tip-to-tip and spike lengths were found to 
be 121.1 ± 9.8 nm and 29.6 ± 7.6 nm, respectively (Table S2). A selected area (electon) 
diffraction (SAED) pattern characteristic of Au crystalline structures was observed from the 
AuNU branch (Figure 2b). With an increase in the aspect ratio of the branches, the L-dopa 
functionalized AuNUs were found to exhibit a broad plasmon spectrum, with a dominant 
longitudinal plasmon resonance peak at 808 nm and a weaker transverse peak at ~ 527 nm 
(Figure 2c). The presence of primary amine and carboxylic acid groups of the L-dopa 
molecules on the surface of the multi-branched AuNUs were confirmed using XPS analysis 
(Figure 2d and e). Control AuNUs were also synthesized using 4-ethylcatechol and were 
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found to have similar morphological and optical properties (Table S2 and Figure S6). As 
expected, XPS analysis confirmed the absence of both primary amine and carboxylic acid 
groups on the surface of the 4-ethylcatechol functionalized AuNUs (Figure 2d and e). The 
Au:Ag ratio on the surface of the AuNUs was determined from Au 4d and Ag 3d core levels 
to be 98:2 for both samples (Figure 2f).   
A major limitation in the development of anisotropic AuNPs such as nanorods, 
nanoprisms, and nanostars for photothermal applications lies in the undesirable ageing 
phenomenon in which the AuNPs tend to rearrange into thermodynamically favorable spheres 
during long term storage or laser-induced heating,33 resulting in the loss of original 
nanoparticle shape, aggregation of nanoparticles, and a resultant blue shift in the UV-vis 
absorption curve. This event has been attributed to the higher surface energy of gold atoms 
arising from the larger surface area in anisotropic AuNPs. In this study, we found that the 
catechol and PEG coating on the surface of the multi-branched AuNUs was able to effectively 
minimize the ageing process as seen from the unchanged UV-vis absorption spectrum over a 
period of 3 months (Figure S6b).  
3.3. Cytotoxicity and LAT-1 targeted cellular uptake. The cytotoxicity of the 
functionalized AuNFs was first evaluated in the human breast cancer cell lines MCF-7 and 
MDA-MB-231 as well as the non-tumorigenic immortalized breast epithelial MCF-10A cell 
line. No overt cytotoxicity was induced by all the functionalized AuNFs of various sizes even 
at supraphysiological concentrations of up to 100 µg/mL equivalent gold content in all three 
cell lines tested (Figure 3 and Figure S7). These results thus demonstrate that the 
functionalized AuNFs are biocompatible and are suitable for biomedical applications.  
To evaluate the LAT-1 targeting efficiency, a panel of breast cancer cell lines including 
MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, and the non-tumorigenic MCF-10A 
cell line were incubated with the respective catechol-functionalized AuNFs and quantified for 
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intracellular gold content using ICP-AES. For each of the three sizes of AuNFs tested, it was 
observed that the L- and D-dopa functionalized AuNFs mediated significantly higher uptake 
in all four breast cancer cell lines when compared to the dopamine and 4-ethylcatechol 
functionalized AuNF controls (P < 0.01; Figure 4a-c). For instance, in the triple negative 
MDA-MB-231 cell line, it was found that approximately 17% of the added dose of both the 
90 nm L-dopa and D-dopa functionalized AuNFs were taken up by the cells while < 1% of 
the dopamine and 4-ethylcatechol functionalized AuNFs were internalized (Figure 4b). The 
higher uptake of both the L- and D-dopa functionalized AuNFs in the breast cancer cell lines 
was consistent with reports on the ability of the LAT-1 to transport both the L and D isomers 
of bulky or branched amino acids in cancer cells.34-35 Notably, minimal uptake of L- and D-
dopa functionalized AuNFs was observed in the non-tumorigenic MCF-10A cell line, hence 
demonstrating the selectivity of the L- and D-dopa functionalized AuNFs towards breast 
cancer cells (Figure 4d). It is also important to note that the LAT-1 targeting capabilities of 
the L- and D-dopa functionalized AuNFs appear to be preserved despite the possible surface 
adsorption of serum proteins on the nanoparticles as discussed in Section 3.1 (Figure S5).  
To further investigate the mode of cellular uptake and intracellular distribution of the L-
dopa and 4-ethylcatechol functionalized AuNFs, thin sections of treated MDA-MB-231 cells 
were prepared and imaged using HAADF-STEM. From Figure 5a and Figure S8, it can be 
observed that membrane invaginations occurred upon contact of the L-dopa functionalized 
AuNFs with the plasma membrane. The L-dopa functionalized AuNFs were predominantly 
found to be concentrated within vesicular structures, hence suggesting an endocytic mode of 
cellular uptake (Figure 5b and c). In contrast, very few of the non-targeting 4-ethylcatechol 
functionalized AuNFs were observed within the cells (Figure 5d). The endocytic mode of 
uptake for the L- and D-dopa functionalized AuNFs was further confirmed by the significant 
decrease in the amount of AuNFs internalized when the incubation temperature was reduced 
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from 37 °C to 4 °C (P < 0.05; Figure S9). In the literature, the clathrin-independent mode of 
endocytosis has been reported for the internalization of heterodimeric LAT-1-4F2hc 
complexes, which are taken into the cells via distinct vesicles that are subsequently 
transferred to early endosomes for sorting.36-37 It is believed that the mild acidic pH of the 
early endosomes then triggers conformational changes in the protein complex causing release 
of its cargo, hence enabling the transporter to be recycled back to the plasma membrane via 
tubular endosomes.  
The role of LAT-1 in mediating uptake of the L-dopa functionalized AuNFs was 
investigated in a competition assay where the uptake of AuNFs by the MCF-7 breast cancer 
cells was determined in the presence of previously reported LAT-1 substrates phenylalanine 
(Phe) or serine (Ser).34 In the presence of the high affinity substrate Phe (Km = 14.2 µM), a 
dose-dependent decrease in the amount of L-dopa functionalized AuNFs internalized was 
observed, with uptake reduced to 84% and 70% of the control in the presence of 2 and 20 mM 
of Phe, respectively (Figure 6a; P < 0.05). The low affinity substrate Ser, on the other hand, 
did not induce significant decrease in the uptake of L-dopa functionalized AuNFs. As the 
concentrations of free amino acids and AuNFs used in this experiment did not induce overt 
cytotoxicity (Figure 3 and 6b), it is likely that the free Phe competed with the L-dopa 
functionalized AuNFs for interaction with the LAT-1, thereby leading to a reduction in 
nanoparticle uptake.  
3.4. Effect of AuNP geometry on cellular uptake. As the size and shape of nanoparticles 
play an important role in influencing their biological properties,38 we next evaluated the effect 
of particle size on the uptake of AuNFs using the MDA-MB-231 breast cancer cells. The 
nanoparticle concentration for a known gold content of each type of AuNF was first estimated 
using NTA (Table S1) and an approximately same number (~ 1.1 × 1010 particles per well) of 
each of the AuNFs was incubated with the cells for 12 h. For each type of functionalization, a 
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size-dependent uptake of the AuNFs was found to occur in the following order: 90 nm > 70 
nm > 46 nm (P < 0.05; Figure S10). For instance, an increase in the diameter of the L-dopa 
functionalized AuNFs from 46 to 70 and 90 nm, resulted in 3.0- and 3.7-fold increase in the 
number of particles taken up per cells, respectively. The influence of nanoparticle shape on 
the uptake of the AuNPs was further evaluated using the functionalized AuNFs and AuNUs 
with similar core diameters of approximately 90 and 84 nm, respectively (Figure 1d, 2a insert 
and Table S2). Whilst the cancer targeting properties of both the L-dopa functionalized 
AuNFs and AuNUs were preserved when compared to the 4-ethylcatechol functionalization, 
an increase in the aspect ratios of the nanoparticle branches from the flower-like to urchin-like 
morphology led to a slight decrease in cellular uptake at both concentrations tested (P < 0.01; 
Figure S11). This result is in agreement with previous studies in which spherical AuNPs or 
AuNPs having a shape closer to a sphere were found to promote greater cellular uptake when 
compared to star-shaped or urchin-like AuNPs in various cell types.38  
3.5. Photothermal properties of functionalized AuNUs. The photothermal properties of 
the L-dopa- and 4-ethylcatechol-functionalized AuNUs were investigated as a function of 
concentration during exposure to an 808 nm continuous wave laser at 3 W for 3 min. As 
shown in Figure 7a, laser irradiation of dispersions containing L-dopa functionalized AuNUs 
resulted in a gradual dose-dependent rise in temperature, with the highest temperature 
increase of 21 °C recorded at 50 µg/mL, while no significant temperature rise was observed 
with Milli-Q water. A similar heating profile was also obtained for the 4-ethylcatechol 
functionalized AuNUs, hence demonstrating that the type of coating did not affect the 
photothermal properties of the AuNUs (Figure S12). In addition, the laser irradiation of the L-
dopa and 4-ethylcatechol functionalized AuNUs did not result in significant changes to the 
core diameter, tip-to-tip length, and the aspect ratio of the branched structures (Table S2). 
These results thus suggest that the coating of the multi-branched AuNUs with L-dopa or 4-
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ethylcatechol and PEG was sufficient to maintain the structural stability of the AuNUs during 
photothermal heating and could potentially reduce the need for repeated nanoparticle dosing 
during the treatment course. 
3.6.  Selective photothermal ablation of breast cancer cells. In order to first simulate a 
situation whereby malignant breast cancer cells are exposed to photothermal agents in the 
interstitial fluids in vivo, L-dopa functionalized AuNUs were added to each well with cells 
adhered at the bottom and immediately subjected to NIR laser irradiation at 9.4 W/cm2. 
Consistent with the thermal profiles observed earlier, the bulk heating of the extracellular 
medium resulted in a concentration-dependent decrease in MDA-MB-231 cell viability; with 
cell viability decreased to 75% at 5 µg/mL, and < 1% from 15 µg/mL and above (Figure 7b). 
To demonstrate targeted photothermal ablation of breast cancer cells by the L-dopa 
functionalized AuNUs, MDA-MB-231 cells were pre-treated with various concentrations of 
AuNUs for three days. Following pre-treatment, only a small amount of non-internalized L-
dopa functionalized AuNUs was found to remain in the extracellular medium as compared to 
the 4-ethylcatechol functionalized AuNUs treated wells (Figure S13a). After rinsing the cells 
thoroughly to remove extracellular AuNUs, ≥ 80% of the added dose of L-dopa 
functionalized AuNUs and ≤ 2% of the 4-ethylcatechol functionalized AuNUs were found to 
be taken up by the cells (Figure S13b). Optical micrographs of the cells before and after laser 
irradiation were also recorded. Figure S14b and c shows the accumulation of dark L-dopa 
functionalized AuNUs granules within cells, while no nanoparticle clusters were visible in the 
untreated and 4-ethylcatechol functionalized AuNUs treated cells (Figure S14a, d, and e). 
Immediately after laser irradiation, the cells that have internalized L-dopa functionalized 
AuNUs appeared rounded up whereas minimal or no changes in cell morphology were 
observed for the untreated cells and cells treated with 4-ethylcatechol functionalized AuNUs 
(right panels of Figure S14b and c vs. Figure S14a, d, and e). An evaluation of the cell 
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viability 24 h after laser irradiation showed that cells that have been pre-treated with 50 and 
100 µg/mL L-dopa functionalized AuNUs had significantly reduced cell viability of 30% and 
16%, respectively (Figure 7c). In contrast, cells treated with the non-targeting 4-ethylcatechol 
functionalized AuNUs were fully viable at the same irradiation dosage (Figure 7d), hence 
clearly demonstrating the ability of the L-dopa functionalized AuNUs to mediate selective 
photothermal ablation of breast cancer cells. In the absence of laser exposure, cells that were 
separately treated with L-dopa- and 4-ethylcatechol-functionalized AuNUs were not found to 
be toxic at the dosages tested. The selective PTT mediated by the L-dopa functionalized 
AuNUs could be further demonstrated by the confined detachment of non-viable cells 24 h 
after laser irradiation, giving rise to a relatively empty zone within the laser spot (outlined by 
white dotted line), while cells outside the zone of laser irradiation remained largely viable 
(Figure 7e). On the other hand, the cell monolayer treated with the non-targeting 4-
ethylcatechol functionalized AuNUs remained fully intact and viable after laser treatment as 
evidenced from the uniform green fluorescent staining of live cells by the cell permeant 
calcein AM dye as well as absence of red fluorescent staining of non-viable cells by the 
ethidium homodimer-1 dye (Figure 7f). These results thus demonstrate that the localized laser 
irradiation of cells that have internalized the LAT-1 targeting AuNUs serves as a secondary 
form of targeting to overcome unwanted side effects frequently observed with traditional 
chemotherapy and hyperthermia therapy. As a proof-of-concept for the use of L-dopa 
functionalized AuNU-mediated PTT to sensitize cancer cells to conventional chemotherapy, 
the pre-treated MDA-MB-231 breast cancer cells were first subjected to laser irradiation and 
subsequently exposed to cisplatin (Cis) and docetaxel (DTX), which are first-line 
chemotherapeutic agents used in the clinical treatment of TNBC. At the highest dose of L-
dopa functionalized AuNU used for pre-treatment, the cells demonstrated a cell viability of 
16% when subjected to PTT alone (Figure 8). Cells treated with Cis alone had cell viability of 
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61%. The combination of PTT and Cis led to a significant reduction in cell viability to 4% (P 
< 0.05), which was less than the 9.8% cell viability expected if the combination effect was 
additive, hence suggesting synergistic effects.39 Similarly, treatment of the cells with DTX 
alone resulted in a cell viability of 84%. The combination of PTT and DTX at the 100 µg/mL 
pre-treatment dose of L-dopa functionalized AuNUs used led to a significant reduction in cell 
viability to 1% (P < 0.01), which was again lower than the 13.4% cell viability expected in 
the case of additive effects. These results were thus consistent with previous reports in which 
PTT was found to increase membrane permeability thereby leading to enhanced drug 
accumulation and cytotoxicity in cancer cells.4, 39  
 
4. Conclusions   
In this study, a simple and versatile method was developed for the synthesis of multi-
branched AuNPs with active cancer targeting capabilities via the LAT-1. By utilizing 
catechol-containing LAT-1 ligands in the seed mediated reduction of gold ions, 
monodispersed nanoflower-like AuNPs with excellent stability, biocompatibility, and 
targeting to a panel of breast cancer cell lines even in the presence of serum-containing media 
were obtained. The direct synthesis of cancer targeting multi-branched AuNPs using LAT-1 
ligands circumvents the need for cytotoxic surfactants as well as additional conjugation 
procedures, hence potentially offering time and cost savings for the large scale production of 
biofriendly AuNPs. Additionally, the introduction of silver ions during synthesis gave rise to 
sea urchin-like AuNPs (AuNUs) with strong absorbance in the NIR window, which enabled 
them to be used in the selective photothermal ablation of the triple negative MDA-MB-231 
breast cancer line. In addition, the PTT mediated by the L-dopa functionalized AuNUs 
sensitized breast cancer cells to the cytotoxic effects of conventional chemotherapeutic agents 
cisplatin and docetaxel. Taken together, the cancer targeting L- or D-dopa functionalized 
23 
 
AuNUs may have potential to be used for the in vivo targeted photothermal ablation of breast 
cancers, especially against the triple negative subtype, for which there is currently no targeted 
therapy. As LAT-1 is frequently overexpressed in numerous proliferating tumors, this 
technology may also have broad applications for the PTT of other cancer types.  
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Figure 1. (a) Catechols employed in the synthesis and functionalization of multi-branched 
AuNPs in this study. (b-d) TEM images of catechol-functionalized AuNFs that were prepared 
using (b) 12.5, (c) 50, and (d) 100 µL of 0.1M HAuCl4·3H2O. Particle size distribution was 
determined from the obtained TEM images using the ImageJ software.    
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Figure 2. Representative (a) TEM image with core measurement (insert), (b) selected area 
electron diffraction (SAED) pattern, and (c) UV-vis absorbance spectrum of L-dopa 
functionalized AuNUs with LSPR peak absorbance tuned towards the NIR region. X-ray 
photoelectron spectroscopy (XPS) spectra obtained for L-dopa and 4-ethylcatechol 
functionalized AuNUs indicating (d) C 1s, (e) N, and (f) Au 4d and Ag 3d core levels. 
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Figure 3. Effect of 90 nm catechol-functionalized AuNFs treatment on cell proliferation in (a) 
MCF-7, (b) MDA-MB-231, and (c) MCF-10A determined using WST-1 assay. 
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Figure 4. Uptake of catechol-functionalized AuNFs by breast cancer cell lines (a) MCF-7, (b) 
MDA-MB-231, (c) MDA-MB-453 and MDA-MB-468 (90 nm), and (d) non-tumorigenic 
MCF-10A treated with 15 µg/mL of AuNFs for 12 h determined using ICP-AES. Results 
represent mean ± standard deviation from at least two independent experiments performed in 
triplicates. 
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Figure 5. HAADF-STEM images of MDA-MB-231 after incubation with 90 nm L-dopa- and 
4-ethylcatechol-functionalized AuNFs. (a) Cellular uptake of L-dopa functionalized AuNFs 
and (b) accumulation of L-dopa functionalized AuNFs inside vesicles after 4 h treatment. (c) 
Similar distribution of L-dopa functionalized AuNFs in vesicles was observed after 12 h 
treatment. (d) Representative cell section showing minimal or no 4-ethylcatechol 
functionalized AuNF uptake even after 12 h treatment. 
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Figure 6. (a) Competitive inhibition of L-dopa functionalized AuNF uptake in MCF-7 in the 
presence of free LAT-1 ligands following 5 h incubation (* P < 0.01; ** P < 0.05). Results 
represent mean ± standard deviation from three independent experiments performed in 
triplicates. (b) Cell viability of MCF-7 following free amino acid treatment for 5 h.  
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Figure 7. Photothermal effects of functionalized AuNUs following laser treatment. (a) 
Heating curve of L-dopa functionalized AuNUs following irradiation with 808 nm laser at 9.4 
W/cm2. (b) Cell viability of triple negative MDA-MB-231 breast cancer cell line exposed to 
increasing concentrations of extracellular L-dopa functionalized AuNUs added just before 
laser irradiation. Cell viability of MDA-MB-231 cells that have internalized (c) L-dopa 
functionalized AuNUs and (d) 4-ethylcatechol functionalized AuNUs with (w/) and without 
(w/o) laser exposure. Confocal scanning laser microscopy images after laser irradiation of 
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MDA-MB-231 that have internalized (e) L-dopa functionalized AuNUs and (f) 4-
ethylcatechol functionalized AuNUs. Live cells are stained green while dead cells appear red. 
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Figure 8. Sensitization of MDA-MB-231 cells to 83 µM cisplatin (Cis) and 100 nM docetaxel 
(DTX) following laser irradiation of cells pre-treated with L-dopa functionalized AuNUs at 
the indicated concentrations (in µg/mL). 
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Multi-Branched Gold Nanoparticles with Intrinsic LAT-1 Targeting Capabilities for 
Selective Photothermal Therapy of Breast Cancer  
 
Zhan Yuin Ong*, Shu Chen, Elham Nabavi, Anna Regoutz, Alexandra Porter, Iain Dunlop, 
David Dexter and Daniel Elson   
 
 
 
Stability testing: 90 nm L-dopa functionalized AuNFs were dispersed in 800 µL of 
deionized water, 1 × PBS (pH 7.4), MEM cell culture medium with 10% fetal bovine serum, 
and 100% FBS at a concentration of 30 µg/mL equivalent Au content, and incubated at 37 °C 
on an orbital shaker (600 rpm) to mimic blood circulation. At 0, 4, 24, 48, and 72 h, the 
hydrodynamic size and polydispersity of the samples were monitored by dynamic light 
scattering. 
Size-dependent uptake of AuNFs: MDA-MB-231 cells were seeded onto 12-well plates 
at a density of 2.5 × 105 cells per well and allowed to adhere overnight. The incubation media 
in each well was replaced with cell culture media containing approximately 1.1 × 1010 of each 
type of AuNFs. After 12 h incubation at 37 ºC, non-internalized AuNFs were removed, and 
the cells were rinsed thoroughly with 1 mL of PBS for 5 times. The cells were then 
trypsinized, rinsed once with PBS, and pelleted by centrifugation at 1300 × rpm for 4 min. 
Trypan blue staining was performed to determine the number of viable cells in each sample. 
The Au content was analyzed by ICP-MS following aqua regia digestion. The number of 
particles internalized per sample was subsequently converted from the Au content obtained 
and normalized by the number of viable cells in each sample. 
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Table S1. Particle size, zeta-potential, and polydispersity index (PDI) of synthesized AuNFs  
Designation AuNP 
functionalization 
Diameter ± 
S.D. (nm)a 
Z-average 
diameter ± 
S.D. (nm)b 
PDIb Zeta-
potential  ± 
S.D. (mV)b 
Concentration 
(particles/mL)c 
46 nm 
L-dopa 47.4 ± 3.6 62.9 ± 0.7 0.17 -39.4 ± 1.2 7.02 × 108 
D-dopa 44.4 ± 4.1 62.6 ± 0.1 0.22 -37.4 ± 0.7 7.30 × 108 
Dopamine 48.4 ± 6.9 55.5 ± 0.1 0.24 -36.5 ± 1.3 7.23 × 108 
70 nm 
L-dopa 71.6 ± 4.2 89.8 ± 0.6 0.05 -41.0 ± 1.5 2.82 × 108 
D-dopa 70.7 ± 3.9 96.9 ± 0.7 0.15 -36.3 ± 0.4 2.99 × 108 
Dopamine 73.3 ± 4.5 89.3 ± 0.5 0.07 -32.9 ± 0.1 3.11 × 108 
4-ethylcatechol 74.8 ± 6.1 88.9 ± 0.8 0.09 -35.1 ± 0.7 3.19 × 108 
90 nm 
L-dopa 89.6 ± 4.1 116.5 ± 0.7 0.02 -34.6 ± 1.0 1.84 × 108 
D-dopa 89.5 ± 4.7  112.6 ± 0.8 0.04 -37.5 ± 0.4 1.80 × 108 
Dopamine 86.2 ± 5.3  111.2 ± 1.1 0.02 -32.6 ± 0.2 1.67 × 108 
4-ethylcatechol 91.9 ± 5.6 108.3 ± 0.1 0.04 -35.3 ± 0.9 1.87 × 108 
a)By TEM measurement; b)By dynamic light scattering; c)Particle concentration of 1 µg/mL 
Au equivalent dispersion determined using NanoSight NTA concentration measurement 
upgrade.  
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Table S2. Quantitative analysis of Ag/AuNP-L-dopa and Ag/AuNP-4-ethylcatechol with and 
without laser exposure using TEM images by ImageJ software. 
Laser irradiation Ag/AuNP type Core diameter 
(nm) 
Tip-to-tip 
length (nm) 
Spike 
length (nm) 
Aspect 
ratio 
Before 
L-dopa 83.9 ± 4.4 
(n=110) 
121.1 ± 9.8 
(n=86) 
29.6 ± 7.6 
(n=58) 
2.2 ± 0.6 
(n=58) 
4-ethylcatechol 83.7 ± 5.7 
(n=194) 
112.3 ± 9.4 
(n=187) 
29.5±8.2 
(n=101) 
1.6 ± 0.4 
(n=101) 
After 
L-dopa 85.5 ± 7.0 
(n=38) 
124.1 ± 9.0 
(n=38) 
32.5 ± 7.9 
(n=34) 
2.2 ± 0.6 
(n=34) 
4-ethylcatechol 84.9 ± 6.2 
(n=133) 
122.3 ± 10.1 
(n=112) 
33.1 ± 8.1 
(n=116) 
1.9 ± 0.5 
(n=116) 
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Figure S1. (a) TEM image with size distribution, and (b) UV-vis absorption spectrum of 
spherical citrate-capped gold seeds synthesized using the Turkevich method. 
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Figure S2. UV-vis absorption spectra of catechol functionalized AuNFs in (a) deionized 
water and (b) 1 × PBS. 
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Figure S3. High resolution TEM (HRTEM) image of 90 nm L-dopa functionalized AuNF 
showing crystal lattice spacing characteristic of Au. 
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Figure S4. X-ray photoelectron spectroscopy (XPS) spectra obtained for various 
functionalized AuNFs, including (a) survey spectrum indicating all core levels as well as (b) 
Au 4f, (c) C 1s, and (d) N 1s core level spectra. 
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Figure S5. Stability of L-dopa-functionalized AuNFs in various biologically relevant media with 
shaking at 37 °C over time. 
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Figure S6. (a) TEM image of 4-ethylcatechol functionalized AuNUs used as non-targeting 
control in the photothermal ablation of breast cancer cells. (b) UV-vis spectrum demonstrating 
stability of the AuNUs upon storage at 4 °C for 3 months. 
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Figure S7. Cell viability of (a-b) MCF-7, (c-d) MDA-MB-231, and (e-f) MCF-10A treated with 
46 nm (a, c and e) and 70 nm (b, d and f) functionalized AuNPs determined using WST-1 assay. 
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Figure S8. Additional HAADF-STEM images showing endocytic uptake of 90 nm L-dopa 
functionalized AuNF by MDA-MB-231.  
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Figure S9. Temperature-dependent uptake of 90 nm functionalized AuNFs by MDA-MB-231 
cells during 4 h incubation. * P < 0.01; ** P < 0.05. 
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Figure S10. Size-dependent uptake of functionalized AuNFs by the MDA-MB-231 cell line 
during the 12 h incubation. * P < 0.01; ** P < 0.05. 
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Figure S11. Effect of ‘nanoflower' (AuNF) vs. ‘nanourchin' (AuNU) morphology for cellular 
uptake of nanoparticles functionalized with (a) L-dopa, and (b) 4-ethylcatechol by MDA-MB-
231. * P < 0.01; ** P < 0.05. 
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Figure S12. Thermal profiles of 4-ethylcatechol functionalized AuNUs at various concentrations 
under laser irradiation.  
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Figure S13. (a) Appearance of sea urchin-like AuNPs (AuNU) dispersions in the tissue culture 
well plates and (b) quantification of intracellular Au content after treatment of MDA-MB-231 
with the indicated concentration of L-dopa and 4-ethylcatechol functionalized AuNUs for 72 h.  
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Figure S14. Bright-field optical micrographs of MDA-MB-231 cells pre-treated with (a) 0, (b) 
50, and (c) 100 µg/mL of L-dopa functionalized AuNUs as well as (d) 50 and (e) 100 µg/mL of 
4-ethylcatechol functionalized AuNUs before and after laser irradiation.  
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